Compare NFGC & FTRE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | NFGC | FTRE |
|---|---|---|
| Founded | 2016 | 1996 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | Precious Metals | Medical Specialities |
| Sector | Basic Materials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 760.5M | 829.3M |
| IPO Year | 2021 | 2023 |
| Metric | NFGC | FTRE |
|---|---|---|
| Price | $1.91 | $13.30 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 9 |
| Target Price | N/A | ★ $14.06 |
| AVG Volume (30 Days) | 1.4M | ★ 1.5M |
| Earning Date | 05-11-2026 | 05-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $2,723,400,000.00 |
| Revenue This Year | $3,542.00 | N/A |
| Revenue Next Year | $118.57 | $3.09 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 1.00 |
| 52 Week Low | $1.39 | $3.97 |
| 52 Week High | $3.59 | $18.67 |
| Indicator | NFGC | FTRE |
|---|---|---|
| Relative Strength Index (RSI) | 40.68 | 55.18 |
| Support Level | $1.85 | $8.85 |
| Resistance Level | $2.14 | $18.26 |
| Average True Range (ATR) | 0.12 | 0.78 |
| MACD | -0.02 | -0.23 |
| Stochastic Oscillator | 4.94 | 9.69 |
New Found Gold Corp is a mineral exploration company engaged in the acquisition, exploration and evaluation of resource properties with a focus on gold properties located in the Provinces of Newfoundland and Labrador and Ontario, Canada. The Companies exploration is focused on discovering and delineating gold resources. The Company has one material property: the Queensway Project located in Newfoundland, Canada (the Queensway Project).
Fortrea is a global, late-stage contract research organization that provides comprehensive phase 1 through phase 4 clinical trial management, clinical pharmacology, and patient access solutions. The company works with emerging and large biopharma, medical device, and diagnostic companies to run their clinical trials as a functional-service provider, full-service provider, and offers hybrid trials. In 2023, Fortrea was formed as an independent, publicly traded company after Labcorp spun off its clinical development business, which it acquired via its purchase of Covance in 2015 for $6.1 billion. Fortrea has 19,000 staff members across 90 countries.